Project Grant R41GM148112
- The National Institute of General Medical Sciences (NIGMS) awarded a $297,664 Phase I Small Business Technology Transfer (STTR) grant to Blotting Innovations, LLC under the Biomedical Research and Research Training program (CFDA 93.859). The purpose of this project is to develop two innovative products for western blotting, a widely used protein analysis technique in biomedical research: A "Gelbrane" cassette that combines a polyacrylamide gel and transfer membrane in a single pre-cast...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
- This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
- This $306,872 Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) supports the development of a 3D printed integrated sample preparation and chromatography platform for proteomics research at Millennial Materials & Devices Inc., a small disadvantaged business located in Stony Brook, New York. The project aims to fabricate customized 3D printed carbon microbead stationary phase materials and additive manufacturing tools to create an integrated...
- This $305,000 STTR Phase I Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop an ultra-sensitive biosensor capable of protein analysis at single-molecule resolution. The biosensor consists of a nanopatterned chip with a proprietary scaffold material that binds and immobilizes molecular targets, which are then detected using surface-enhanced Raman spectroscopy (SERS). This innovation seeks...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop an automated system to streamline the sample preparation process for liquid biopsy cancer testing. The $305,000 award will fund the creation of a microfluidic-based instrument that automates the bisulfite conversion step, a critical but time-consuming and error-prone process in preparing circulating tumor DNA for epigenetic...
- This SBIR Phase I project, funded by a $305,000 award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a microchip-based technology for complex, multidimensional cell reprogramming. The project seeks to create a miniaturized liquid and cell handling system that leverages acoustic-electric micro-vortices to precisely and sequentially deliver genetic molecules, making advanced cell engineering more accessible across...
- Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA program 93.859 Biomedical Research and Research Training provides $350,000 to Fluidispec LLC to develop a new microfluidic/nanofluidic sample preparation platform. The goal is to improve single-cell and low-input proteomics analysis by enabling efficient extraction of proteins from cells, removal of contaminants, and improved protein denaturation. This platform is expected to enhance...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of a novel in-line biomanufacturing process analytical technology tool. The $302,417 award to Physical Sciences Inc. (PSI), in collaboration with the University of Massachusetts Lowell (UML), aims to enable real-time monitoring of biomolecules in large-scale bioreactors for gene therapy manufacturing. The technology...
ACCESSIBLE AND ROBUST HIGH-THROUGHPUT WESTERN BLOTTING FOR SMALL SAMPLE SIZES - PROJECT SUMMARY THE GOAL OF THIS PHASE I STTR IS FOR BLOTTING INNOVATIONS, LLC TO ESTABLISH FEASIBILITY OF A COMMERCIALIZABLE MESOWESTERN-A HIGH-THROUGHPUT, AFFORDABLE WESTERN BLOTTING TECHNIQUE THAT WE RECENTLY DEVELOPED. WESTERN BLOTTING IS A TECHNIQUE FOR MOLECULAR-WEIGHT-RESOLVED ANALYSIS OF PROTEINS AND THEIR POST-TRANSLATIONAL MODIFICATIONS THAT IS PRACTICED TODAY ALMOST IDENTICALLY TO WHEN IT WAS FIRST INTRODUCED IN THE LATE 1970S. IT REMAINS ONE OF THE MOST WIDELY-USED PROTEIN ASSAYS ACROSS BIOMEDICAL RESEARCH, PERHAPS THE MOST USED IN THE PAST 10 YEARS. MAJOR REASONS ARE THAT IT IS LOW-COST, OFTEN A GOLD STANDARD, AND WELL-ESTABLISHED IN MOST LABS. YET, WESTERN BLOTTING HAS BEEN REFRACTORY TO SCALE UP, TYPICALLY LIMITED TO ~10 SAMPLES PER RUN. CAPILLARY ELECTROPHORESIS-BASED SEPARATION IN AUTOMATED APPARATI HAS BEEN DEVELOPED THAT INCREASE THROUGHPUT WITH SMALLER SAMPLES, BUT ARE EXPENSIVE AND CAN BE SENSITIVE TO SAMPLE PREPARATION. THE MICROWESTERN USES PIEZOELECTRIC PIPETTING FOR UP TO 96 BLOTS AT A TIME IN A STANDARD FOOTPRINT; HOWEVER, THE PIEZOELECTRIC APPARATUS IMPOSES CAPITAL COST AND TECHNICAL DIFFICULTLY DETERRENTS. WE ESTABLISHED THE MESOWESTERN THAT ANALYZES OVER 300 SAMPLES WITH A SIMILAR FOOTPRINT, AFFORDABILITY, AND EASE-OF-USE AS TRADITIONAL WESTERN BLOTS, AND WITH ~10-FOLD LOWER SAMPLE SIZE REQUIREMENTS. OUR MAIN PRODUCTS ARE A PRECAST MESOWESTERN GEL THAT IS LOADABLE BY A LOW-COST PIPETTING ROBOT (OPENTRONS) AND A NOVEL YET AFFORDABLE TANK FOR IMMERSED HORIZONTAL ELECTROPHORESIS OF THE LOADED PRECAST GEL. A MAIN INNOVATION IS A CUSTOMIZABLE GEL CASTING DEVICE THAT PRODUCES POLYACRYLAMIDE GELS WITH HUNDREDS OF ~1 UL WELLS, AND ASSOCIATED PROTOCOLS FOR ROBUST GEL CASTING AND ELECTROPHORESIS. ANOTHER MAIN INNOVATION IS IMMERSED HORIZONTAL TANK ELECTROPHORESIS FOR POLYACRYLIMIDE GELS; ONLY SEMI-DRY HORIZONTAL (MICROWESTERN) OR IMMERSED VERTICAL TANK (TRADITIONAL) ARE CURRENTLY AVAILABLE. PHASE I HYPOTHESIS. CAN PRECAST MESOWESTERN GELS BE ROBUSTLY-LOADED ROBOTICALLY, AND THEN SUBJECTED TO IMMERSED HORIZONTAL TANK ELECTROPHORESIS? WE HYPOTHESIZE THAT THIS CAN BE ACCOMPLISHED BY DESIGNING A RIGID INSERT THAT HOLDS THE GEL DURING CASTING AND SHIPPING BUT ALSO FITS INTO (I) OPENTRONS PIPETTING ROBOTS AND (II) A LOW-COST, HORIZONTAL IMMERSED ELECTROPHORESIS APPARATUS. WE HAVE TWO AIMS THAT WILL ESTABLISH FEASIBILITY OF THE PRODUCT BY TESTING THIS HYPOTHESIS. IN AIM 1, WE WILL ESTABLISH ROBUST ROBOTIC LOADING OF SHIPPED, PRECAST MESOWESTERN GELS. WE FOCUS ON OPENTRONS MICROPIPETTING ROBOTS THAT ARE EASY TO USE AND VERY AFFORDABLE. IN AIM 2, WE WILL ESTABLISH ROBUST ELECTROPHORESIS OF ROBOTICALLY-LOADED MESOWESTERN GELS. SUCCESS IN EACH AIM IS DEFINED BY VARIABILITY (CV%) ACROSS ANALYTES AND TECHNICIANS TO BE
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/10/24 | ||
| Not listed | $288.8k | 9/21/22 | ||
| Not listed | $288.8k | 9/21/22 |